NYSEAMERICAN:VNRXVolitionRX Stock Price, Forecast & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRX in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for VolitionRX.

VolitionRX is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for VolitionRX.

VolitionRX Ltd (NYSEAMERICAN:VNRX) posted its quarterly earnings results on Thursday, May, 7th. The medical research company reported ($0.14) EPS for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.04. The medical research company had revenue of $0.54 million for the quarter. View VolitionRX's earnings history.

3 brokerages have issued 12 month price targets for VolitionRX's shares. Their forecasts range from $7.00 to $10.00. On average, they expect VolitionRX's share price to reach $8.33 in the next year. This suggests a possible upside of 122.2% from the stock's current price. View analysts' price targets for VolitionRX.

News headlines about VNRX stock have trended somewhat negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. VolitionRX earned a news impact score of -1.5 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about VolitionRX.

VolitionRX saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 544,700 shares, an increase of 26.3% from the June 15th total of 431,200 shares. Based on an average daily volume of 299,600 shares, the days-to-cover ratio is presently 1.8 days. Currently, 2.0% of the shares of the company are short sold. View VolitionRX's Current Options Chain.

Some companies that are related to VolitionRX include Spectral Medical (EDT), ANGLE (AGL), Proteome Sciences (PRM), DiaSorin (DIA), Polarityte (COOL) and Premaitha Health (NIPT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other VolitionRX investors own include Chesapeake Energy (CHK), Bausch Health Companies (BHC), Verastem (VSTM), Bausch Health Companies (BHC), Ring Energy (REI), Ring Energy (REI), Crispr Therapeutics (CRSP), Exelixis (EXEL), Gilead Sciences (GILD) and ContraFect (CFRX).

VolitionRX trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."

Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VNRX stock can currently be purchased for approximately $3.75.

VolitionRX has a market capitalization of $154.52 million. VolitionRX employs 44 workers across the globe.

The official website for VolitionRX is www.volitionrx.com.

The medical research company can be reached via phone at 646 650 1351.